Laura Kirby

Loss of <i><scp>CDKN</scp>2A</i> expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the <scp>CDK</scp>4/6 inhibitor <scp>PD</scp>0332991 in melanoma cell lines

Richard J. Young, Kelly Waldeck, Claire Martin et al. · Pigment Cell & Melanoma Research · 2014 · 204 citations · Full text

CDK4/6 Inhibition Promotes Antitumor Immunity through the Induction of T-cell Memory

Emily J. Lelliott, Isabella Y. Kong, Magnus Zethoven et al. · Cancer Discovery · 2021 · 120 citations

Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma

Shatha AbuHammad, Carleen Cullinane, Claire Martin et al. · Proceedings of the National Academy of Sciences · 2019 · 116 citations · Full text

Chemoprevention Strategy, Cancer Biology, Tumor Biology +17

Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP

Carleen Cullinane, Kelly Waldeck, Laura Kirby et al. · Scientific Reports · 2020 · 80 citations · Full text

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance

Claire Martin, Carleen Cullinane, Laura Kirby et al. · International Journal of Cancer · 2017 · 72 citations

Braf Combination, Mek Inhibitors, Medicine +15